Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Obsessive-Compulsive Disorder (OCD)

LSD for Obsessive-Compulsive Disorder (OCD)

7 papers and 0 clinical trials exploring lsd as a treatment for obsessive-compulsive disorder (ocd).

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationAbout 1-2% of the population worldwide.

Obsessive-Compulsive Disorder (OCD)

Recent research indicates that psychedelics, particularly psilocybin, are emerging as potential therapeutic agents in the treatment of Obsessive-Compulsive Disorder (OCD). Early clinical trials demonstrate promising results regarding their efficacy and safety, paving the way for future studies in this field.

Full Obsessive-Compulsive Disorder (OCD) profile

Academic Research

7 papers
Open Accessindividual

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Analysing nationally representative YRBSS data from 2001–2019 (125,550 students), 8.4% of adolescents reported lifetime hallucinogen use, declining from 13.3% to 7.0% over the period. Hallucinogen users had significantly higher odds of feeling sad or hopeless, suicidal ideation and planning, and markedly greater co‑occurring use of alcohol, tobacco, cannabis and other illicit drugs.

Published
December 5, 2022
Journal
Children
Authors
Desai, S., Jain, V., Xavier, S., Du, W.
Open Accessmeta

Default Mode Network Modulation by Psychedelics: A Systematic Review

This systematic review shows that classical psychedelics (LSD, psilocybin, ayahuasca) consistently cause acute disruption of resting-state connectivity within the Default Mode Network and increase cross-network functional connectivity, but it remains unclear how central DMN modulation is to their therapeutic effects. The article synthesises existing evidence and highlights gaps to guide future mechanistic research.

Published
October 22, 2022
Journal
International Journal of Neuropsychopharmacology
Authors
Gattuso, J. J., Perkins, D., Ruffell, S. G. D., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D. J., Sarris, J.
Paywallindividual

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults

This double-blind study (n=22) investigated the effects of microdosing LSD (13μg & 26μg) on resting-state electroencephalography (EEG) and event-related potential (ERP) in healthy adults. The study found that microdoses of LSD produced desynchronization patterns similar to those reported with higher doses of psychedelics, leading the authors to believe that microdoses of LSD may produce therapeutic effects in the absence of a full psychedelic experience.

Published
October 6, 2021
Journal
Psychopharmacology
Authors
Perry, C. M., Malina, M.
Open Accessindividual

Use of psilocybin (“mushrooms”) among US adults: 2015-2018

Pooled 2015–2018 NSDUH data from 168,650 US adults show 9.68% reported lifetime psilocybin use, with higher prevalence among bisexual-identifying individuals and substantial overlap with LSD, methamphetamine and heroin users. These findings can inform harm-reduction efforts and behavioural‑health messaging.

Published
May 11, 2021
Journal
Journal of Psychedelic Studies
Authors
Yockey, R. A., King, K. A.
Paywallmeta

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

This systematic review (2020) looked at 10 modern studies (n=188) on psychedelics (psilocybin, ayahuasca, LSD) for the treatment of a variety of mental health disorders. The review found the studies to provide evidence for efficacy (up to months later) and safety.

Published
October 30, 2020
Journal
Acta Psychiatrica Scandinavica
Authors
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J., Erritzoe, D.
Paywallindividual

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

In a Swiss compassionate-use programme of 18 patients (mainly with PTSD and major depression), LSD (100–200 µg) and MDMA (100–175 mg) administered in group psychotherapy produced pronounced alterations of consciousness and increases across mystical-experience scales on the 5D-ASC and MEQ. Acute subjective responses were largely comparable to those seen in healthy volunteers and clinical-trial patients, supporting further controlled studies of substance-assisted psychotherapy.

Published
October 8, 2020
Journal
Journal of Psychopharmacology
Authors
Schmid, Y., Gasser, P., Oehen, P., Liechti, M. E.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and Obsessive-Compulsive Disorder (OCD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all Obsessive-Compulsive Disorder (OCD) trials Full LSD profile Full Obsessive-Compulsive Disorder (OCD) profile